Bezafibrate — The Pan-PPAR Agonist
Bezafibrate is a synthetic lipid-lowering drug that acts as a pan-agonist for all three PPAR isoforms, playing a crucial role in regulating lipid and glucose metabolism. In the context of longevity, it is of interest for its ability to stimulate mitochondrial biogenesis and improve metabolic flexibility, which has been shown to extend lifespan and delay age-related decline in animal models.
Mechanism of Action
Bezafibrate is a pan-agonist of peroxisome proliferator-activated receptors (PPARα, PPARγ, and PPARδ). By activating these nuclear receptors, it upregulates the PPAR/PGC-1α pathway, which drives mitochondrial biogenesis, enhances fatty acid β-oxidation, and improves cellular energy metabolism. It also exhibits anti-inflammatory properties by inhibiting the expression of pro-inflammatory cytokines such as TNF-α and IL-6. In animal models, this metabolic reprogramming has been shown to delay aging-like phenotypes and extend lifespan.
Human Trial Evidence
No published human longevity trials. Animal/in-vitro evidence only. In humans, bezafibrate has been extensively studied for primary biliary cholangitis and dyslipidemia, demonstrating improvements in liver biochemistry and lipid profiles, but its effects on human aging biomarkers remain uncharacterised.
Dosing Protocol
400 mg/day is the standard clinical dose for dyslipidemia and primary biliary cholangitis. Typically taken once daily or divided into 200 mg twice daily. Requires a prescription. Protocol parameters for longevity are unestablished in humans.
Safety & Contraindications
Generally well-tolerated, but known adverse effects include gastrointestinal distress, myopathy, and elevated liver enzymes. Contraindicated in patients with severe hepatic or renal impairment, and those with pre-existing gallbladder disease. Concomitant use with statins increases the risk of rhabdomyolysis. Requires a prescription.